Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced its financial results for the first quarter ended March 31, 2014.
“We made important progress in the first quarter on our two lead programs - Kerydin and AN2728,” said Paul Berns, President and Chief Executive Officer of Anacor Pharmaceuticals. “We have had a constructive dialogue with the FDA throughout its review of our New Drug Application for Kerydin, and we are preparing for Kerydin’s launch later this year, pending FDA approval.
Help employers find you! Check out all the jobs and post your resume.
